CNS Drug Discovery Market Size, Share and Trends 2026 to 2035

CNS Drug Discovery Market Size and Forecast 2026 to 2035

The global CNS drug discovery market size was calculated at USD 9.80 billion in 2025 and is predicted to increase from USD 10.86 billion in 2026 to approximately USD 27.55 billion by 2035, expanding at a CAGR of 10.90% from 2026 to 2035. The rising prevalence of CNS disorders, the integration of AI and ML in drug discovery, and increased government support for clinical trials and funding are significant factors driving market growth.

Key Takeaways

• North America led the CNS drug discovery market with a share of 43% in 2025.
• Asia-Pacific is expected to be the fastest-growing region with a CAGR of 14% in the forecasted duration.
• By drug type, the small molecules segment led the market with 52% share in 2025.
• By drug type, the gene therapies segment is expected to be the fastest growing, with a CAGR of about 16.5% in the coming years.
• By indication, the Alzheimer's disease segment accounted for the highest revenue share of 24% in 2025 and is expected to be the fastest-growing with a CAGR of 13.5% in the foreseeable period.
• By the discovery stage, the preclinical development segment held the largest revenue share of 28% in 2025 and is expected to grow at the fastest CAGR of 12.5% in the forthcoming years.
• By technology, the high-throughput screening (HTS) segment accounted for the highest revenue share of 29% in the CNS drug discovery market in 2025.
• By technology, the AI-enabled drug discovery segment is expected to be the fastest-growing, with a CAGR of 18.6% in the foreseeable period.
• By end user, the pharmaceutical companies segment held the largest revenue share of 48% in 2025.
• By end user, the biotechnology companies segment is expected to grow at the highest CAGR of 13.8% from 2026 to 2035.

Market Overview

CNS drug discovery provides researchers and healthcare professionals with critical insights into major areas of drug therapies for the treatment of neurological and psychiatric disorders. Furthermore, drug concentration is influenced by numerous factors, such as the permeability of the blood-brain barrier, the structure of brain tissue, and individual physiological processes. The growing prevalence of neurological disorders and lack of biomarkers are propelling the growth of the market.

Impact Of Artificial Intelligence on the CNS Drug Discovery Market

Artificial Intelligence (AI) has swiftly transformed the medicinal chemistry workflow. AI-based predictive tools can evaluate pharmacokinetic properties, metabolic stability, and safety issues at early development stages, enabling chemists to discard fewer promising candidates before proceeding to synthesis or in vitro and in vivo testing. In addition, Machine learning algorithms are increasingly used to analyze multiomics data, identify disease modules, and map the complex networks of protein-protein and protein-drug interactions that contribute to neurodegeneration.

CNS Drug Discovery Market Trends

• Interactive Adoption of Computer-Aided Drug Design: The interactive uptake of computer-aided drug design technologies is changing the CNS therapeutics discovery landscape by allowing more precise, scalable, and data-driven development approaches.
• Expanding Regulatory Support for Regenerative Therapies: Developers and sponsors of biologically derived therapies are increasingly leveraging the advanced therapy designation in regenerative medicine, which fosters the progression of innovative regenerative treatment strategies.
• Emergence of Advanced Biomarkers and Novel Mechanisms of Action: The rise of well-validated biomarkers, including blood-based and digital markers for CNS disorders, as well as imaging and EEG-based biomarkers for neuropsychological conditions, is enhancing our understanding of diseases and facilitating therapeutic development. At the same time, the investigation of novel mechanisms of action is paving the way for targeting historically challenging neurological conditions.

Market Report Coverage and Key Metrics

Market Dynamics

Drivers

Technology-Led Transformation in CNS Therapeutic Development

The rising incidence of neurological disorders, combined with advancements in artificial intelligence, intensive machine learning, and biomarker discovery technologies, is significantly propelling the market. These innovations are enhancing research efficiency, speeding up therapeutic development, and fostering patient-centered treatment solutions.

Restraint

Clinical Setbacks and Blood-Brain Barrier Challenges

The elevated clinical failure rates of CNS drugs, coupled with the complexities of the blood-brain barrier, continue to hinder effective drug delivery to the brain. This scenario presents considerable scientific, regulatory, and commercialization challenges within the landscape of CNS drug discovery and development.

Opportunity

Personalized and Non-Invasive Therapies

The rise of telemedicine, personalized medicine, and nanoparticle-based targeted drug delivery systems is aiding in the development of safer, non-invasive, and more effective therapies for the central nervous system. This progress is not only expanding treatment options but also drawing significant research investments and spurring innovation in neurological treatment technologies.

Market Segmentation Analysis

Drug Type Insights

The Small Molecules Segment Led the Market with 52% of Market Share in 2025

The small molecules segment led the CNS drug discovery market with a share of 52% in 2025, due to well-established pathways for CNS drug development. These small molecules are important in the treatment of CNS disorders because of their ability to effectively cross the blood-brain barrier and their high oral bioavailability. Its lower manufacturing complexity and strong track record of commercial success also reinforce its market dominance.

The biologics segment held 26% of the market share in 2025 and is expected to grow at a CAGR of 12.8% during the forecast period, driven by an increasing emphasis on disease-modifying therapies and notable advancements in treating neurodegenerative diseases. Biologics have the potential to repair or modulate dysfunctional neural systems, and innovations in blood-brain barrier technologies, along with enhanced target specificity, are further driving this segment's growth.

The gene therapies segment held 14% of the market share in 2025 and is expected to be the fastest-growing segment with a CAGR of 16.5% from 2026 to 2035, driven by the rising adoption of precision medicine and advancements in viral vector technologies. Gene therapy is gaining traction for its ability to correct genetic mutations and modulate host protein production for treating CNS diseases. The increasing focus on rare neurological diseases and growing regulatory support are also contributing to the market's expansion.

Indication Insights

The Alzheimer's Disease Segment Held the Largest Market Share of 24% in 2025

The Alzheimer's disease segment dominated the CNS drug discovery market with a share of 24% in 2025 and is expected to witness the fastest growth in the market with a CAGR of 13.5% over the forecast period, driven by an aging global population and a significant unmet need for effective therapies. With over 10 million new dementia cases emerging each year, equating to one every 3.2 seconds, there's a pressing demand for solutions. The increase in biomarker-based research and strong investments in disease-modifying therapies are crucial factors propelling this market forward.

CNS Drug Discovery Market Share, By Indication, 2025-2035 (%)

The Parkinson's disease segment held nearly 16% of the market share in 2025 and is expected to grow at a CAGR of 12.4% in the forecast period, fuelled by a rising prevalence of the disease. Approximately 90,000 individuals are newly diagnosed each year, and the rates of disability and death related to Parkinson's disease are escalating. The development of neuroprotective therapies, the expansion of gene therapy programs, and a rise in research collaborations are all contributing to this market's growth.

The epilepsy segment accounted for 12% of the market share in 2025 and is expected to expand rapidly in the market with a CAGR of 8.7% in the coming years, driven by the ongoing need for innovative anti-seizure medications. With around 50 million people affected globally, epilepsy ranks as one of the most prevalent neurological disorders. The expansion of precision treatment approaches, increased research activity focused on paediatric epilepsy, and heightened awareness of the disease are all supporting the growth of this market.

Discovery Stage Insights

The Preclinical Development Segment Dominated the Market with 28% of Market Share in 2025

The preclinical development segment dominated the CNS drug discovery market with a share of 28% in 2025 and is expected to grow with the highest CAGR of 12.5% in the market during the studied years, due to the expanding CNS therapeutic pipeline and rising investments in translational research. Preclinical studies are essential for evaluating the safety, efficacy, and potential side effects of a target compound or medical intervention before human trials commence. Additionally, there is an increasing focus on biologics and gene therapy programs, along with a growing reliance on advanced disease models.

The lead identification segment accounted for approximately 24% of the market share in 2025 and is expected to grow at a robust CAGR of 10.2% in the forecast period, driven by the increasing adoption of high-throughput screening methods and the expansion of compound libraries. In this phase, a lead compound is identified based on its desirable pharmaceutical activity, paving the way for its development into a potential drug. The surge in computational drug discovery and heightened pharmaceutical R&D activities further bolsters this segment.

The target identification and validation segment accounted for 26% of the market share in 2025 and is expected to grow at a CAGR of 10.2% in the coming years, driven by an increase in genomics research and the expansion of biomarker discovery. This initial phase of drug discovery focuses on pinpointing targets, followed by intensified efforts to validate them. The rising adoption of AI platforms and a deeper understanding of CNS pathways are key contributors to this growth.

Technology Insights

The High-Throughput Screening (HTS) Segment Led the Market with 29% of Market Share in 2025

The high-throughput screening (HTS) segment led the CNS drug discovery market with a share of 29% in 2025, due to its extensive capabilities for evaluating compounds on a large scale and its well-established discovery workflows. HTS has become a pivotal tool in the realm of pharmaceutical drug discovery, moving away from traditional trial-and-error methods to more effectively identify therapeutic targets and validate biological effects. The rise in automation and the expansion of CNS compound libraries further bolster its dominance.

CNS Drug Discovery Market Share, By Technology, 2025-2035 (%)

The genomics and proteomics segment held 23% of the market share in 2025 and is expected to grow at a CAGR of 10.4% in the coming years, driven by the increasing identification of novel targets and the rising adoption of precision medicine. Genomics plays a crucial role in identifying genetic variants that influence disease risk and treatment responses, while proteomics uncovers protein functions and interactions, paving the way for targeted therapies. The expansion of omics databases and growing research into neurological diseases are also driving this segment's growth.

The AI-enabled drug discovery segment accounted for approximately 18% of the market share in 2025 and is expected to be the fastest-growing segment with a CAGR of 18.6% in the forecast period, attributed to the accelerated use of artificial intelligence and machine learning in target identification, significantly enhancing prediction accuracy. Algorithms such as Naïve Bayes, Support Vector Machines, Random Forest, and K-nearest neighbours are being employed in CNS drug discovery. The reduction in drug development timelines and increased pharmaceutical investments are further supporting this growth.

End User Insights

The Pharmaceutical Companies Segment Held the Largest Market Share of 48% in 2025

The pharmaceutical companies segment held the largest revenue share of 48% in the CNS drug discovery market in 2025, driven by substantial investments in CNS research and development, along with robust clinical capabilities. Additionally, the expansion of neurodegenerative pipelines and the cultivation of partnerships with biotech firms further enhance their position. The focus on collaborative opportunities with regulatory agencies also paves the way for continued growth.

The biotechnology companies segment achieved around 31% of the market share in 2025 and is expected to be the fastest-growing segment with a CAGR of 13.8% from 2026 to 2035, supported by innovative advancements in novel CNS targets and an increase in venture capital funding. A strong emphasis on precision medicine, coupled with the expansion of gene and cell therapy research and strategic collaborations with pharmaceutical companies, supports this upward trend.

The academic and research institutes segment accounted for approximately 14% of the market in 2025 and is expected to grow at a CAGR of 9.6% in the coming years, supported by rising funding for neuroscience research and the expansion of translational medicine programs. Additionally, initiatives focused on biomarker discovery, strong government backing, and partnerships between academia and industry are key factors driving this segment's expansion.

Market Regional Analysis: North America, Europe, Asia-Pacific

U.S. CNS Drug Discovery Market Size and Growth 2026 to 2035

The U.S. CNS drug discovery market size was evaluated at USD 3.35 billion in 2025 and is projected to reach around USD 9.42 billion by 2035, growing at a CAGR of 10.11% from 2026 to 2035.

North America: Dominated with 43% of Market Share in 2025

North America held a major revenue share of 43% in the CNS drug discovery market in 2025, driven by a robust pipeline for CNS drug development and significant R&D investments from pharmaceutical companies. Additionally, the rising prevalence of neurological disorders and a sophisticated biotechnology ecosystem further solidify the region's dominance.

U.S. Market Analysis

The U.S. leads the North American market, supported by substantial investments in drug development that enhance treatment options and expand therapeutic classes. Many novel drugs are being developed by U.S. enterprises, and extensive clinical trials conducted within the country enrich treatment pipelines, fostering growth.

How is Asia-Pacific Growing in the CNS Drug Discovery Market?

Asia-Pacific held 21% of the market share in 2025 and is expected to show the fastest growth with a CAGR of 14% over the forecast period, driven by the increasing prevalence of neurological diseases, particularly the alarming rise of Alzheimer's among the elderly in China, India, and neighbouring South Asian and Western Pacific countries. The rapid expansion of the biotechnology sector, coupled with rising clinical research investments and the emergence of pharmaceutical innovation hubs, supports this market momentum.

China Market Analysis

China is emerging as the leader in the Asia-Pacific market due to the rising prevalence of neurological disorders. Pharmaceutical companies are making significant investments in drug discovery, and the expansion of specialty drug pipelines targeting neurodegenerative and psychiatric conditions is contributing to revenue growth. Furthermore, increasing healthcare expenditures and improved insurance coverage are enhancing patient access.

Which Factors Drive the CNS Drug Discovery Market in Europe?

Europe held 28% of the market share in 2025 and is expected to expand significantly in the market with a CAGR of 10.2% in the coming years, supported by the increasing burden of neurodegenerative diseases, the expansion of neuroscience research programs, strong academic-industry collaborations, and a supportive regulatory environment.

Germany Market Analysis

Germany stands out in the European market, with its university hospitals serving as key clinical trial sites for CNS drug development programs. Initiatives like the AMNOG health technology assessment framework provide structured pathways for market access to CNS therapies that demonstrate added therapeutic benefits.

Will the Middle East and Africa Grow in the CNS Drug Discovery Market?

The Middle East and Africa held 3% of the market share in 2025 and is expected to grow at a considerable CAGR of 9.6% in the upcoming period, driven by increasing healthcare research investments and a heightened focus on neurological healthcare, further supported by the expansion of biotechnology infrastructure.

UAE Market Analysis

The UAE is experiencing remarkable market growth, propelled by the rising prevalence of neurological disorders, advancements in CNS drug development, increasing healthcare expenditures, and growing awareness of CNS disorders. Urban retail strategies and rural NGO partnerships are improving access, while collaborations with global pharmaceutical companies and enhanced clinical research capabilities continue to support market development.

Latin America: 5% Market Share in 2025

Latin America held 5% of the market share in 2025 and is considered to be a significantly growing area, due to increased participation in clinical research and heightened awareness of neurological diseases, alongside the expansion of pharmaceutical R&D activities that bolster market growth.

Brazil Market Analysis

Brazil is witnessing robust market growth, driven by the rising prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, depression, and epilepsy among the aging population. Contributing factors include increasing healthcare expenditures, improvements in healthcare infrastructure, and a growing awareness of mental health issues.

Market Competitive Landscape: Leading Companies and Strategies

The CNS drug discovery market is characterized as semi-consolidated, featuring a range of established global players who are actively involved. Many companies are primarily concentrating on Alzheimer's disease and neuropsychiatric conditions, while also broadening their efforts toward Parkinson's disease. Additionally, there is a growing emphasis on gene therapies and advanced molecular targeting for neurodevelopmental disorders.

However, the high investment costs and the lengthy process from drug discovery to commercialization present significant challenges. CNS drugs also encounter difficulties in penetrating the blood-brain barrier, which poses a substantial hurdle in the market. Nevertheless, numerous stakeholders and contract research organizations (CROs) are engaged in research aimed at treating CNS disorders. Furthermore, advancements in blood-brain barrier technologies and the integration of AI-driven diagnostic tools are paving the way for new opportunities in this evolving market.

CNS Drug Discovery Market Companies

• Eli Lilly and Company
• Roche
• Novartis
• Pfizer
• AbbVie
• Biogen
• Bristol Myers Squibb
• Johnson & Johnson Innovative Medicine
• Otsuka Pharmaceutical
• Takeda Pharmaceutical
• UCB
• Neurocrine Biosciences
• Acadia Pharmaceuticals
• Denali Therapeutics
• Alkermes

Recent Developments CNS Drug Discovery Market (2025-2026)

• In June 2026, Deep Science Ventures (DSV) and Medicine Discovery Catapult (MDC) joined forces to tackle the challenges of delivering medicines to the brain. This collaboration merges DSV's innovative venture-building model with MDC's extensive drug discovery expertise and infrastructure, with the goal of creating new strategies to ensure that transformative medicines effectively reach the brain.(Source: https://www.genengnews.com)
• In February 2026, Insilico Medicine announced exciting AI drug discovery collaborations with China Medical System (CMS), focusing on multiple projects related to the central nervous system (CNS) and autoimmune diseases. The two companies are set to collaborate on the development of at least two research and development (R&D) programs, leveraging Insilico Medicine's advanced AI platform in conjunction with CMS's clinical development expertise.(Source: https://www.pharmaceutical-technology.com)

Segments Covered in the Report

By Drug Type

• Small Molecules
• Biologics
• Gene Therapies
• Cell Therapies

By Indication

• Alzheimer's Disease
• Parkinson's Disease
• Epilepsy
• Multiple Sclerosis
• Schizophrenia
• Depression and Anxiety Disorders
• Others

By Discovery Stage

• Target Identification and Validation
• Lead Identification
• Lead Optimization
• Preclinical Development

By Technology

• High Throughput Screening (HTS)
• Genomics and Proteomics
• AI-enabled Drug Discovery
• Biomarker-based Discovery
• CRISPR and Gene Editing Platforms

By End Use

• Pharmaceutical Companies
• Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations (CROs)

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa